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Objectives The objective of this study was to document the prevalence of chronic venous insufficiency (CVI) and its associ-
ated factors in adults with Fontan physiology.
Background As the population of adults with complex congenital heart disease and Fontan physiology increases, so does the
occurrence of highly morbid and mortal outcomes, including heart failure and thromboembolism. The presence
of abnormal peripheral hemodynamic conditions in this population and their potential contribution to adverse
outcomes is not well known. The primary objective of this study was to document the prevalence of CVI in adults
with Fontan physiology.
Methods A total of 159 adults with Fontan physiology from 7 adult congenital heart centers were prospectively assessed
for lower extremity CVI, with the assignment of clinical, etiological, anatomical, and pathophysiological classifi-
cation grades, and compared with age-matched and sex-matched controls. Leg photographs were independently
reassessed to confirm interobserver reliability.
Results The prevalence of CVI was significantly greater in the Fontan population (60%; 95% confidence interval [CI]: 52%
to 68%) compared with healthy controls (32%; 95% CI: 15% to 54%) (p  0.008). Strikingly, the prevalence of
severe CVI (clinical, etiological, anatomical, and pathophysiological grade 4) was significantly higher in the
Fontan group (22%; 95% CI: 16% to 29%) versus the healthy controls (0%; 95% CI: 0% to 14%) (p  0.005). In a
multivariate analysis, several factors were independently associated with severe CVI, including increased num-
bers of catheterizations with groin venous access, lower extremity itching, and deep venous thrombosis.
Conclusions CVI is common in adult patients with congenital heart disease with Fontan physiology. The contribution of abnor-
mal peripheral hemodynamic conditions to comorbidities, including thromboembolism and heart failure, and
interventions to improve peripheral hemodynamic conditions require further exploration. (J Am Coll Cardiol
2010;56:144–50) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.048o
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She Fontan operation has evolved over the past 4 decades from
alliation for tricuspid atresia to its wider current application
or many single-ventricle circulations (1). Gradual attrition in
urvival in adults with Fontan physiology is related to throm-
oembolism, heart failure and sudden death (2), whereas loss
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emodynamic status, alterations in neurohormonal activation,
nd imbalance in ventilatory function (3–7).
More recently, there has been recognition of the potential
mpact of changes in peripheral hemodynamic conditions,
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July 6, 2010:144–50 Venous Disease in Adult Fontan Patientskeletal muscle metabolism, and endothelial dysfunction on
he failing Fontan physiology. Endothelium-dependent cir-
ulating levels of von Willebrand factor, flow-mediated
ilation, and blood flow supply to skeletal muscle with
ubsequent effect on exercise capacity have all been shown to
e abnormal in patients with Fontan palliation (8–11).
See page 151
Chronic venous insufficiency (CVI) is a common clinical
roblem. In the general population, CVI is associated with
reduced quality of life, particularly in relation to pain,
epression, social isolation, mobility, and physical function
12). Several pathophysiologic mechanisms appear common
o the occurrence of both CVI and Fontan failure, including
bnormalities in central and peripheral hemodynamic status.
owever, to date, CVI has not been described in patients
ho have undergone the Fontan procedure.
Risk factors for CVI in the general population (including
eredity, age [13–15], female sex, leg trauma, obesity,
istory of phlebitis or deep vein thrombosis [16], pregnancy
17], oral contraceptive use, and prolonged standing) and
ymptoms referable to CVI (including aching, heaviness, a
ensation of swelling, and skin irritation) can be determined
y clinical history. Inspection and palpation define physical
ndings to further classify CVI. CVI can be thereby
dentified and graded according to a well-established scale
escribing clinical, etiological, anatomical, and pathophys-
ological (CEAP) classifications (18,19).
The objective of this study was to document the preva-
ence of CVI and its associated factors in adults with Fontan
hysiology. The hypothesis was that patients with Fontan
hysiology have chronically elevated systemic venous pres-
ure, and this finding in the setting of nonpulsatile pulmo-
ary blood flow may place them at increased risk for CVI.
hese results may further elucidate the complex relation-
hips between central and peripheral hemodynamic condi-
ions, as well as provide a foundation for future studies
iming to improve functional outcomes in this population.
ethods
tudy design. This multi-institutional, cross-sectional, ob-
ervational study prospectively recruited successive subjects
ge 18 years who had previously undergone Fontan
rocedures and presented in stable condition for outpatient
valuation at 1 of 7 U.S. adult congenital heart disease
enters for evaluation. The protocol was developed by the
ore institution (Children’s Hospital Boston, Boston, Mas-
achusetts) and was refined by the consensus of participating
enters within the Alliance for Adult Research in Congen-
tal Cardiology framework (20). Subjects were excluded if
hey had histories of cardiac transplantation or had major
urgery or traumatic injury within the previous 10 weeks.
linical, anatomical, and surgical data were collected atnrollment (July 2007 to May 2009) by medical record Ceview and patient interview us-
ng standardized forms. Control
ubjects consisting of hospital
mployees without histories of
ongenital heart disease were
dentified and enrolled. A com-
arison group of subjects cared
or by the core institution who
ad previously undergone tetral-
gy of Fallot (TOF) surgical re-
air were also included. The pro-
ocol was approved by each center’s institutional review
oard, and written informed consent was obtained.
ecruitment protocol. Standardized case report forms in-
luded basic demographic information, congenital cardiac
natomical diagnosis as designated by the treating center
sing standardized nomenclature (21), surgical procedures
ncluding type of Fontan operation, current medications,
amily history of venous disease, and symptoms. Laboratory
alues and historical imaging data that were collected within
year of enrollment were included.
A directed physical examination was performed, includ-
ng a thorough evaluation of the subjects’ lower extremities
ith the assignment of CEAP classification grades by the
nvestigator at each center. The clinical signs in the affected
egs are categorized into 7 classes designated C0 to C6
Table 1) (18). Patients with CEAP grades 4 are catego-
ized as having severe CVI, given the presence of end-organ
hanges from lipodermatosclerosis to ulceration (22).
Each center used a digital camera to photograph the
ower extremities according to a standardized protocol. The
hotographs were taken at a distance of 1 to 2 feet from
he subject while he or she was standing in 4 distinct
ositions. Additional photographs were taken at close range
f any ulcers, discoloration, or other skin changes.
nterobserver agreement. To test agreement of CEAP
lassification by each center, a vascular medicine specialist
M.G.H.) blinded to the subjects’ assigned CEAP classifi-
ations reviewed 50 randomly selected subjects and deter-
ined CEAP grades on the basis of visual inspection of the
hotographs provided.
tatistical analysis. Continuous demographic and clinical
ata are summarized as mean  SD or as medians and
EAP ClassificationTable 1 CEAP Classification
Class Characteristics
0 No visible or palpable signs of venous disease
1 Telangiectasias or reticular veins
2 Varicose veins
3 Edema
4a Skin changes ascribed to venous disease (pigmentation, eczema)
4b Skin changes including lipodermatosclerosis and/or atrophie blanche
5 Skin changes as defined above with healed venous ulcer
6 Skin changes as defined above with active venous ulcer
Abbreviations
and Acronyms
CEAP  clinical,
etiological, anatomical, and
pathophysiological
CI  confidence interval
CVI  chronic venous
insufficiency
TOF  tetralogy of FallotEAP  clinical, etiological, anatomical, and pathophysiological.
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Venous Disease in Adult Fontan Patients July 6, 2010:144–50nterquartile ranges depending on normality. Categorical
ata are reported as percents. Patient characteristics were
ompared between the Fontan group and the control and
omparison groups using t tests, chi-square tests, and Fisher
xact tests, as appropriate. CVI was defined as CEAP grade
1 and severe CVI as CEAP grade 4. The prevalence of
VI in the Fontan group was compared with the control
nd comparison groups using chi-square or Fisher exact
ests. The rates of severe venous insufficiency were similarly
ompared.
Within the group of Fontan patients, univariate logistic
egression was used to identify demographic and clinical risk
actors of the binary outcome of severe CVI. Factors with
nivariate p values 0.05 were considered for inclusion in a
ultivariate logistic regression model. To prevent overfit-
ing, only models with at most 3 predictors were considered.
he final model was the one that maximized the likelihood
core statistic.
Interobserver agreement among the subset of patients
ho were re-reviewed was quantified with the weighted
appa coefficient. For all tests, statistical significance was
efined by a 2-sided p value0.05. Statistical analyses were
erformed using SAS version 9.2 for Windows (SAS
nstitute Inc., Cary, North Carolina).
esults
verall cohort. A total of 159 adults with Fontan physi-
logy were enrolled at 7 U.S. adult congenital centers. The
ontrol and comparison groups were enrolled at the core
enter and consisted of 25 healthy subjects without heart
isease and 40 subjects with repaired TOF. The baseline
haracteristics of this cohort are summarized in Table 2.
he mean age (32.1  7.6 years), sex distribution (40%
ale), and body mass index (23.1  2.5 kg/m2) were
tatistically comparable between the healthy control group
p NS) and the Fontan cohort. No subjects in the healthy
ontrol group had undergone prior cardiac catheterization.
he repaired TOF group had a similar sex distribution (40%
ale) and mean body mass index (25.7  5.9 kg/m2) (p 
S), but they were slightly older (mean age 35.6  10.7
ears; p  0.003) than the Fontan group. The repaired
OF group had a median of 4 (interquartile range 2 to 6)
Baseline Characteristics of Fontan, TOF, and HeTable 2 Baseline Characteristics of Fontan,
Characteristic
Fontan
(n  159)
Age at enrollment (yrs) 30.6 9.1 3
Age at surgical repair* (yrs) 8.3 (4.3–15.2) 5
Male sex 73 (46%) 1
Body mass index (kg/m2) 24.2 4.5 2
Cardiac catheterizations 5 (3–7)
Presence of leg symptoms 85 (54%) 1
Data are expressed as mean  SD, median (interquartile range), or n
complete repair of tetralogy of Fallot (TOF).ardiac catheterizations with prior groin access. Forty per- Aent of the repaired TOF group reported lower extremity
ymptoms, compared with only 1 patient (4%) in the
ealthy control group.
Table 3 summarizes the anatomical and clinical charac-
eristics in the Fontan subjects. The 159 Fontan subjects
ere 30.6  9.1 years of age at enrollment. The mean body
ass index of the cohort was 24.2  4.5 kg/m2, and the
ean resting oxygen saturation was 92.6  4.3%. The
istribution of ventricular morphologic subgroups was as
ollows: left ventricle, 71%; right ventricle, 26%; and mixed,
%. Eighty-three percent of subjects had undergone some
Control Subjectsand Healthy Control Subjects
F
40) p Value
Healthy
(n  25) p Value
10.7 0.003 32.1 7.6 0.43
–10.0) 0.007
) 0.50 10 (40%) 0.58
5.9 0.14 23.1 2.5 0.10
) 0.03 0 (0–0) 0.0001
) 0.13 1 (4%) 0.0001
ge at surgical repair indicates age at Fontan completion surgery and
ontan Subjectsna omical and Clinical CharacteristicsTable 3 Fontan SubjectsAnatomical and Clinical Characteristics
Characteristic
Fontan Patients
(n  159)
Cardiac diagnosis
Tricuspid atresia 54 (34%)
Double-inlet LV 41 (26%)
Heterotaxy syndrome 21 (13%)
Hypoplastic left heart syndrome 4 (2%)
Unbalanced atrioventricular canal 4 (2.5%)
Pulmonary atresia, intact ventricular septum 3 (1.9%)
Other single ventricle 32 (20.6%)
Type of Fontan procedure
Atriopulmonary 70 (44%)
Lateral tunnel 57 (36%)
Atrioventricular 13 (8%)
Extracardiac conduit 9 (6%)
Other 10 (6%)
Vascular history
Deep venous thrombosis 10 (6.5%)
Fontan pathway thrombosis 24 (15.7%)
Pulmonary thrombus/embolism 10 (6.5%)
Medication use
Antiarrhythmic agents 54 (34.2%)
ACE inhibitors/ARBs 84 (53.2%)
Beta-blockers 39 (31%)
Diuretic agents 71 (44.9%)
Warfarin 91 (57.6%)
Aspirin 70 (44.3%)
Intracardiac devices
Pacemaker 57 (35.8%)
Internal defibrillator 2 (1.3%)althyTOF,
TO
(n 
5.6
.7 (1.5
6 (40%
5.7
4 (2–6
6 (40%CE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; LV  left ventricle.
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July 6, 2010:144–50 Venous Disease in Adult Fontan Patientsurgical palliation before Fontan completion. The mean
ge at the initial Fontan procedure was 11.2  9.3 years,
nd the most common types of Fontan procedures per-
ormed were atriopulmonary anastomosis and intracardiac
ateral tunnel. Twenty-eight patients had undergone subse-
uent Fontan revision, and 31 had undergone subsequent
ontan fenestration closure. Subjects in the cohort had
ndergone a median of 5 (interquartile range 3 to 7) cardiac
atheterizations with femoral intravenous access, and 10%
ad documented femoral venous occlusion. Of the 147
atients who had imaging data within 1 year of enrollment,
ver 40% of the cohort had at least mild systemic ventricular
ysfunction, and 70% had at least mild atrial ventricular
alve regurgitation.
On direct questioning regarding symptoms relating to
ystemic venous disease and health, 85 subjects (54%)
eported at least 1 of the following: burning, swelling, pain,
tching, or leg heaviness. Thirty-five percent of the cohort
as involved in activities that required long periods of
tanding. Ten subjects had histories of deep venous throm-
osis of the lower extremity, and 10 additional subjects had
eceived diagnoses of pulmonary emboli in the past. Addi-
ionally, 24 subjects had histories of thrombosis in the
ontan pathway, and 9 had experienced cerebral vascular
ccidents after Fontan completion. Forty percent reported
amily histories of lower extremity venous disease. Twenty-
hree percent had histories of tobacco abuse, 10% had
iabetes, and 27% of the women had completed at least 1
regnancy.
revalence. The prevalence of CVI was significantly
reater in the Fontan population (60%; 95% confidence
nterval [CI]: 52% to 68%) compared with healthy controls
Figure 1 35-Year-Old Woman, Status Post-Fontan Revision
to an Extracardiac Conduit 3 Years Before Enrollment
Clinical, etiological, anatomical, and pathophysiological (CEAP)
grade 4 with skin pigmentation and lipodermatosclerosis.32%; 95% CI: 15% to 54%) (p  0.008). Strikingly, therevalence of severe venous insufficiency (CEAP grade 4)
Figs. 1 to 3) was significantly higher in the Fontan cohort
22%; 95% CI: 16% to 29%) versus the healthy control
roup (0%; 95% CI: 0% to 14%) (p  0.005). There was no
ifference in the prevalence of CVI between the Fontan
roup (22%; 95% CI: 16% to 29%) and the subjects with
epaired TOF (12.5%; 95% CI: 4% to 27%) (p  0.27).
nivariate and multivariate predictors of severe CVI in the
ontan population are summarized in Table 4. The kappa
alue was 0.76 for interobserver CEAP classification. Of
mportance, 100% concordance was observed for patients
enoted as having severe disease (CEAP grade 4).
iscussion
his multi-institutional, prospective, cross-sectional assess-
ent is the first to document the high prevalence of CVI in
dults with congenital heart disease and Fontan physiology;
trikingly, the point prevalence of severe CVI in the Fontan
opulation examined in this study approached 25%. This
ppears to be more than 3 to 4 times higher than the point
revalence of severe CVI reported in the general population,
lthough it approximates that seen in other groups (older
ge, deep venous thrombosis) thought to be at high risk for
evere CVI (12,23). Of interest, this prevalence of severe
VI in our cohort is similar to that reported for systemic
enous pathway thrombosis in a single-center study of adult
ontan outpatients (24).
Several mechanisms contribute to the development and
aintenance of CVI, each of which is particularly relevant
o adult survivors with Fontan circulation. Pressure in lower
Figure 2 41-Year-Old Man Status Post-Right Atrial Appendage
to Pulmonary Artery Fontan at Age 18 Years
CEAP grade 5 with healed skin ulceration. Abbreviation as in Figure 1.
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Venous Disease in Adult Fontan Patients July 6, 2010:144–50xtremity veins is determined by 2 components: hydrostatic
orces related to the weight of the column of blood from the
ight atrium to the foot and a hydrodynamic determinant
elated to pressures generated by contractions of the skeletal
uscles of the leg and the pressure in the capillary network
25). Concomitant with the development of CVI, cellular
ctivation and cytokine release involving leukocyte interac-
ion with the endothelium lead to an inflammatory and
otentially destructive process involving pathways similar to
hose activated in chronic heart failure syndromes (26).
The hydrostatic component to the elevation of systemic
enous pressures may be increased in patients with Fontan
alliation because of several factors. This unique circulatory
odel intricately ties the loading conditions of the central
ump to loading conditions in the systemic veins, in
ontrast to the normal circulation, which has an intervening
ump in the subpulmonary position. By the very definition
f this physiology, right atrial pressure is greater than left
trial pressure, leading to a reversal of the typical trend seen
Figure 3 43-Year-Old Man Status
Post-Atriopulmonary Fontan Procedure at Age 5 Years
CEAP grade 6 with extensive skin changes and area of active ulceration.
Abbreviation as in Figure 1.n normal subjects, as well as to increased systemic venous pressure. Any additional resistance to flow, from the pe-
ipheral systemic veins through the right atrium and lungs,
eads to further elevation of hydrostatic pressure in the
ystemic veins. With increasing heart rates, survivors with
ontan circulation demonstrate limited inotropic response
nd worsening of diastolic filling of the systemic arterial
ump, leading to elevation of left atrial pressure and,
ecause of direct coupling across the pulmonary vascular
ed, elevation in central venous pressure (4). Reduction of
ormal respiratory changes in transhepatic systemic venous
ow and an increase in transhepatic venous resistance,
bserved in adult survivors with Fontan physiology, may
urther exacerbate distal systemic venous pressures (27).
aken together, the elevation of distal and more proximal
ystemic venous pressures leads to distention and engorge-
ent of the veins, increased pressure on local tissue, and
ltimate induction of inflammation in the vascular wall,
enous valves (with development of valve remodeling, loss of
unction, and reflux) (28–30) and local tissues.
Additional hydrodynamic components leading to devel-
pment of CVI in Fontan circulations have been less
xamined. Inai et al. (8) recently demonstrated altered
keletal muscle hemodynamic conditions in patients with
ontan palliation, although calf pump function was not
pecifically explored. Systemic venous valve dysfunction,
aused by high systemic venous pressures and inflammatory
icrocirculation changes outlined previously, likely contrib-
te to increased risk for venous thromboembolism and, as
ell, are likely worsened by the heightened occurrence of
uch venous thromboembolism in patients with Fontan
alliation (due in part to circulating prothrombotic factors
31]) throughout the Fontan pathway (2).
The recognition and cataloguing of CVI in the popula-
ion of adult congenital heart disease survivors is a new
nding and was aided by the collaborative efforts of a
ulti-institutional research network. Multiple patient fac-
ors were identified as predictors of severe CVI, including
ge, male sex, and prior occurrence of deep venous throm-
osis. Adult survivors with Fontan palliation frequently
nderwent catheterization using venous access at a much
ounger age and smaller vessel size than the population of
ther adults with CVI and associated coronary atheroscle-
osis (typically using arterial access), potentially leading to
reater degrees of venous obstruction and inflammation and
ltimately to increased occurrence of CVI.
Interestingly, cardiac findings traditionally considered to
e risk factors for adverse outcomes in adults with Fontan
hysiology did not correlate with increased risk for CVI.
hese include morphologic systemic ventricle type and
urgical type of Fontan procedure (atriopulmonary anasto-
osis vs. lateral tunnel procedure). Additionally, prescribed
atient use of anticoagulant agents did not predict the
everity of CVI.
One concerning, although important, finding in this
ohort is the lack of a significant difference between the
revalence of CVI in the adult Fontan population compared
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July 6, 2010:144–50 Venous Disease in Adult Fontan Patientsith the comparison group of adults with repaired TOF.
he high prevalence of CVI in this slightly older latter
roup suggests that these patients, as well, may have adverse
eripheral hemodynamic status, which remains to be ex-
lored. Patients with repaired TOF are a limited compari-
on population given the combination of potential con-
ounding effects such as elevated systemic venous pressures
nd subpulmonary ventricular dysfunction that may exist in
his group.
Adults with Fontan physiology are among the most
hallenging groups followed in adult congenital clinics, with
igh morbidity and mortality. Thromboembolism, exercise
ncapacity, and heart failure appear common and increase
oth in incidence and severity over time. The association
etween peripheral hemodynamic status, CVI, and endo-
helial dysfunction may prove to both depend on, as well as
ontribute to, the long-term consequences and decreased
unctional capacity (32) associated with Fontan physiology.
As was shown by assessment of the comparison group
ith TOF, examination of this unique patient population
nderscores the importance of examining the peripheral
irculation in all adult patients with congenital heart disease,
o determine its contribution to mechanisms of heart failure
nd exercise intolerance. Ultimately, recognition and deter-
ination of the mechanisms of CVI in survivors with
ontan palliation may lead to the assessment of interven-
ions with proven benefit in the general CVI population
such as dedicated lower extremity muscle training exercises
nd venous compression stockings) in the Fontan popula-
ion. Pharmacological therapies to decrease systemic venous
ressure have not been shown to be effective in the general
opulation, but the benefit of such therapies on the occur-
ence of highly morbid and mortal outcomes in the Fontan
Univariate and Multivariate Predictors for SeverTable 4 Univariate and Multivariate Predicto
Variable
Univariat
Odds Ratio
(95% CI)
Male sex 2.42 (1.12–5.25)
Age 31 yrs 6.54 (2.80–15.27)
Single right ventricle 0.41 (0.15–1.13)
Atriopulmonary Fontan 3.64 (1.36–9.79)
Atrioventricular Fontan 5.31 (1.31–21.57)
Extracardiac Fontan 2.43 (0.41–14.47)
Other Fontan type 0.95 (0.10–8.80)
Catheterizations 5 5.68 (2.30–14.02)
Lower extremity itching 10.12 (4.30–23.82)
Diuretic agent use 5.01 (2.16–11.62)
Antiarrhythmic agent use 2.99 (1.38–6.46)
Heart failure diagnosis 2.46 (1.12–5.40)
History of DVT 6.15 (1.63–23.24)
History of venous surgery 3.78 (0.73–19.63)
Body mass index 1.11 (1.12–1.20)
CI  confidence interval; CVI  chronic venous insufficiency; DVT  dopulation remains unknown. mtudy limitations. This study had several important limi-
ations. This cross-sectional observational study was per-
ormed at 7 major adult congenital heart centers. The study
atient population may not be representative of all adults
ith Fontan physiology in the general community, because
f a referral bias. However, it is recognized that the majority
f patients with Fontan palliation remain in care at such
nstitutions. Furthermore, this study was limited to mea-
urements at a single physical assessment. Therefore,
hanges in systemic venous health and disease over time
ould not be assessed. However, this study lays the ground-
ork for the implementation of longitudinal examination of
he functional relationships and potential interventions in
his population. Given a possible association between CVI
nd mortality, survivor bias is a concern. This would tend to
ias the findings toward a lower proportion of patients with
VI, however, because those who died would likely have a
igher prevalence of CVI.
Finally, the lack of significant difference between the
revalence of CVI in the adult Fontan population compared
ith the comparison group of adults with repaired TOF
ay reflect the age difference between the 2 groups or a lack
f power in the study due to inadequate sample size.
onclusions
VI is common in adult congenital heart patients with
ontan physiology and is often severe. The occurrence of
VI in other populations of adults with congenital heart
isease, as well as the contribution of abnormal peripheral
emodynamic conditions in adult survivors with Fontan
alliation to comorbidities including thromboembolism and
eart failure, and interventions to improve peripheral he-
in Fontan Patientsr Severe CVI in Fontan Patients
Multivariate
p Value
Odds Ratio
(95% CI) p Value
0.02
0.0001
0.07
0.03
0.0002 5.40 (1.92–15.18) 0.001
0.0001 11.13 (4.25–29.11) 0.0001
0.0001
0.005
0.03
0.007 5.80 (1.29–26.01) 0.02
0.12
0.01
ous thrombosis.e CVIrs fo
eodynamics require further exploration.
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